Drugs
Orion Genomics has initiated partnerships with renowned researchers at Washington University in St. Louis, Missouri, to discover novel biomarkers for early cancer detection. The collaborations aim to identify "Second Code" biomarkers, which include DNA methylation patterns that indicate the presence of cancer and its responsiveness to certain therapies.
Drugs
Acorda Therapeutics has strengthened its senior leadership with two key additions: Gerard A. Cignarella as Vice President of Business Development and Herbert Henney III, PharmD, as Vice President of Medical Affairs. Cignarella brings a rich background in marketing and business development, having previously worked at Pfizer and Regions Limited Incorporated.
Drugs
The partnership between NeoRx Corporation (NERX) and The Scripps Research Institute marks the first collaboration at Scripps Florida, focusing on the discovery of novel, small-molecule, multitargeted, protein kinase inhibitors as therapeutic agents, including cancer treatments. This research alliance will be supported by a $2.5 million grant from NeoRx over
Drugs
AutoGenomics, Inc., and Targeted Molecular Diagnostics, Inc., have formed a 3-year development partnership to create novel cancer biomarkers for oncology. The collaboration will leverage the AutoGenomics INFINITI platform to develop tests for pharmaceutical and biotech companies, which will aid in the preclinical and clinical development of targeted therapies. The first
Drugs
VNUS Medical Technologies, Inc., a pioneer in medical devices for treating venous reflux disease, has become a member of the Nasdaq Health Care Index, announced on July 27, 2005. As one of the initial companies to join this index, VNUS is part of a list of 545 companies that meet
Drugs
Nitric oxide synthase II has been identified as a potential therapeutic agent for cancer treatment due to its ability to repel metastasis despite promoting angiogenesis. Researchers at the University of Texas MD Anderson Cancer Center have developed a gene therapy approach using adenoviral vectors to deliver the NOS II gene
Drugs
A new study has found that combining a cancer vaccine with hormone-deprivation therapy can help patients with recurring prostate cancer. The clinical trial, led by scientists at the National Cancer Institute (NCI), was conducted to treat patients with nonmetastatic prostate cancer who were experiencing rising levels of prostate-specific antigen (PSA)
Drugs
Telik, Inc. announced positive interim data from two ongoing phase 2 clinical studies evaluating Telcyta in combination with standard chemotherapy for the treatment of advanced non-small cell lung cancer. The data were presented at the Eleventh World Conference on Lung Cancer in Barcelona, Spain. One trial evaluated the combination of
Drugs
The New England Journal of Medicine recently published results from a pivotal phase III study demonstrating that Tarceva (erlotinib) improves survival in patients with advanced non-small cell lung cancer (NSCLC). The study, conducted by the U.S. National Cancer Institute of Canada Clinical Trials Group, involved 86 sites from 17
Drugs
The American Association for Cancer Research (AACR) firmly believes that stem cell research, including research involving human embryonic stem cells, is crucial for advancing cancer research. AACR's position statement emphasizes the importance of continued experimentation with human stem cells to improve the evaluation of anticancer drugs, identify markers
Drugs
Recent research in the United States and Japan has led to significant breakthroughs in cancer therapy, with study results highlighting the effectiveness of PTEN gene therapy in treating prostate cancer, as well as the antitumor activity of ZD6474 in lung adenocarcinoma cell lines. The studies, published in Cancer Detection and
Drugs
Researchers from the Institute of Cancer Research in England have discovered two novel small molecule inhibitors that can knock down hypoxia-related tumorigenesis. The inhibitors, NSC-134754 and NSC-643735, were identified through a high-throughput screen of 2,000 compounds and were shown to target hypoxia-inducible factor-1 (HIF-1) activity and protein induced by
